



## **CORONA Remedies Limited**

(Formerly known as CORONA Remedies Private Limited)

**Regd. Office:** CORONA House

C- Mondeal Business Park, Near Gurudwara, S.G. Highway,  
Thaltej, Ahmedabad 380 059. Gujarat, India.

**Tele.:** +079 - 40233000

**Online at :** [Info@coronaremedies.com](mailto:Info@coronaremedies.com)

**website :** [www.coronaremedies.com](http://www.coronaremedies.com)

**CIN :** L24231GJ2004PLC044656

March 30, 2026

To,  
Listing Operation Department  
BSE Limited  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai - 400001  
(Scrip Code: 544644)

To,  
Listing Compliance Department  
National Stock Exchange of India Limited  
Exchange Plaza, C-1, Block G, Bandra Kurla  
Complex, Bandra (East), Mumbai - 400051  
(SYMBOL: CORONA)

Dear Sir / Madam,

**Sub.: Press Release**

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Press Release titled **“CORONA Remedies announces strategic acquisition of Wokadine® in India”** being issued by the Company.

The press release is also being made available on the website of the Company at [www.coronaremedies.com](http://www.coronaremedies.com)

You are requested to take note of the above.

Thanking you.

Yours faithfully,

For **CORONA Remedies Limited**

Chetna Dharajiya  
Company Secretary and Compliance Officer

Encl.: A/a

## PRESS RELEASE

### CORONA Remedies announces strategic acquisition of Wokadine® in India

- CORONA Remedies acquires Wokadine® from Dr. Reddy's
- This marks the fifth acquisition by CORONA Remedies
- CORONA Remedies will leverage Wokadine®'s legacy of 46 years of trust and protection
- Increases equity among Surgeons, ENT, General Physicians & Gynaecologists
- This acquisition is a synergy to existing core therapeutic areas

**Ahmedabad, March 30, 2026:** CORONA Remedies Limited (BSE: 544644, NSE: CORONA), today announced the acquisition of Wokadine® from Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY), a global pharmaceutical company headquartered in Hyderabad, India.

Effective March 30, 2026, the acquisition of Wokadine®, ranked #2 in the Povidone Iodine India market<sup>1</sup>, reinforces CORONA's commitment to 'Healing' as the journey towards holistic recovery and health. This strategic acquisition enables CORONA Remedies to penetrate deeper into targeted specialty and offer wider accessibility. This brand holds strong potential for accelerated growth under CORONA Remedies' stewardship.

Integrating Wokadine® into its portfolio marks CORONA Remedies' entry into the INR 648 Cr<sup>1</sup> Povidone Iodine market.

CORONA Remedies' sales & marketing team along with extensive distribution network will work to ensure that this newly acquired portfolio reaches patients across metro, semi-metro, urban, semi-urban and rural areas. Wokadine® comprises of 14 SKUs having different applications, helping clinicians treat the ailing community. This acquisition will be fully funded through Company's internal accruals and cash.

Commenting on the acquisition, **Mr. Tejas Kothari, Vice President – Corporate Strategy & Business Development** said:

*"At CORONA Remedies, we continuously assess both organic and inorganic growth opportunities, focusing on strengthening our brands by leveraging CORONA's extensive reach, strong trust among doctors and the medical fraternity, a pan-India distribution network, and a dedicated sales and marketing team.*

*We believe this acquisition will enhance and strengthen our existing product portfolio. By building on our strong relationships with healthcare professionals, we aim to deepen market penetration and are confident in accelerating the growth of this brand."*

---

<sup>1</sup> Pharmatrac MAT Feb'26

**About CORONA Remedies Limited:**

CORONA Remedies Limited, founded in 2004, is an India focused branded pharmaceutical formulation company engaged in developing, manufacturing & marketing products in women's healthcare, cardio-diabetes, pain management, urology and other therapeutic areas.

CORONA manufactures products for healthcare solutions as per international quality standards in its WHO-GMP/EU GMP-certified plant. CORONA has 2 DSIR-approved R&D centres with team of 100+ scientists working on new formulation development. CORONA is a proud family of 5000+ employees.

To know more about us, visit [www.coronaremedies.com](http://www.coronaremedies.com)

For further information, please contact: Mr. Sagar Shroff, Strategic Growth Advisors Private Limited (SGA), Mobile: 98205 19303 and Email Id: [sagar.shroff@sgapl.net](mailto:sagar.shroff@sgapl.net)

Disclaimer: Certain statements contained in this document may be statements of future expectations and other forward-looking statements that are based on management's current view and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. None of CORONA Remedies Limited or any of its affiliates, advisors or representatives shall have any liability whatsoever (in negligence or otherwise) for any loss howsoever arising from any use of this document or its content or otherwise arising in connection with this document. This document does not constitute an offer or invitation to purchase or subscribe for any shares and neither it nor any part of it shall form the basis of or be relied upon in connection with any contract or commitment whatsoever.

CORONA Remedies Limited expressly disclaims any obligation to update or revise these forward-looking statements to reflect new information or future events, except as required by law.

\*\*\*\*\*